Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report

Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report

Various immune-related adverse events can frequently occur, which may be life-threatening if programmed death 1 or its ligand is blocked. Here, we report a rare case of concomitant autoimmune hemolytic anemia and hemophagocytic lymphohistiocytosis caused by atezolizumab plus chemotherapy in a patien...

Full description

Bibliographic Details
Main Authors: Yoshinari Endo, MD, Yusuke Inoue, MD, PhD, Masato Karayama, MD, PhD, Yasuyuki Nagata, MD. PhD, Hironao Hozumi, MD, PhD, Yuzo Suzuki, MD, PhD, Kazuki Furuhashi, MD, PhD, Noriyuki Enomoto, MD, PhD, Tomoyuki Fujisawa, MD, PhD, Yutaro Nakamura, MD, PhD, Naoki Inui, MD, PhD, Takafumi Suda, MD, PhD
Format: Article
Language:English
Published: Elsevier 2022-01-01
Series:JTO Clinical and Research Reports
Subjects:
Immune checkpoint inhibitors
Lung cancer
Autoimmune hemolytic anemia
Hemophagocytic lymphohistiocytosis
Case report
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364321001223

Internet

http://www.sciencedirect.com/science/article/pii/S2666364321001223

Similar Items